Intelligence Profile
Science
Mechanism of Action
The combination of CJC-1295, Ipamorelin, and AOD-9604 represents three distinct peptides that target different pathways related to growth hormone signaling and metabolism. However, evidence for this specific triple combination is extremely limited.
Based on the available research on individual components:
CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that works by binding to GHRH receptors in the anterior pituitary gland. This binding stimulates the release of endogenous growth hormone through the cyclic adenosine monophosphate (cAMP) pathway.
Ipamorelin functions as a selective ghrelin receptor agonist (growth hormone secretagogue receptor). It mimics the action of ghrelin by binding to these receptors in the pituitary, triggering growth hormone release without significantly affecting cortisol or prolactin levels.
AOD-9604 is a modified fragment of human growth hormone (specifically amino acids 176-191) that was designed to retain the lipolytic (fat-burning) properties of growth hormone while eliminating its growth-promoting effects. It appears to work by stimulating lipolysis and inhibiting lipogenesis in adipose tissue.
Critical Evidence Limitations: The provided research focuses on peptide therapies in musculoskeletal and orthopedic applications generally, but does not contain specific mechanistic data for this particular combination. No clinical trials were retrieved for this compound mixture.
The theoretical rationale combines growth hormone stimulation (CJC-1295 + Ipamorelin) with targeted fat metabolism effects (AOD-9604), but the actual synergistic effects, optimal ratios, and combined pharmacokinetics of this specific triple combination lack robust scientific documentation.
This information is for educational purposes only and should not replace professional medical consultation.